Trial Profile
Relative Bioavailability of Two FDC Tablet Strengths of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin and Metformin Extended Release Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin/linagliptin/metformin (Primary) ; Empagliflozin; Linagliptin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 08 Feb 2017 Status changed from active, no longer recruiting to completed.
- 26 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2016 Status changed from not yet recruiting to recruiting.